Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NEW U.S. Patent Issued to Dyadic International

Published: Tuesday, March 25, 2014
Last Updated: Tuesday, March 25, 2014
Bookmark and Share
The Patent is entitled “Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose”.

Dyadic International, Inc. announced today that it has been issued U.S. Patent No. 8,673,618 entitled, "Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose" by the United States Patent and Trademark Office ("USPTO").  

This new patent provides broader intellectual property rights relating to compositions and methods of developing and producing novel enzymes which efficiently convert different sources of plant biomass (e.g. corn stover, wheat straw and bagasse) to fermentable sugars. These sugars can be used in the production of advanced biofuels and bio-based chemicals. 

Methods include processes for degrading plant material using enzyme mixtures and specified enzyme combinations. Enzyme compositions are used to break down specific components of plant biomass (e.g. cellulose, hemi-cellulose, and lignin) into a variety of fermentable sugars.

In addition to claims covering the production of these patented enzymes using Dyadic's C1 Expression System, a wide variety of additional production methods are covered including bacteria, yeast, algae, other fungi and plants.

Dyadic's President and CEO, Mark Emalfarb, stated, "Plant biomass provide a plentiful source of potential energy in the form of sugars that can be utilized to produce advanced biofuels and bio-based chemicals. This latest patent further broadens our family of patents that address the advanced biofuels and bio-based chemicals market. This latest patent also expands our comprehensive intellectual property portfolio further protecting our C1 Expression System, and the products derived therefrom.  We anticipate that broadening our rights for these applications will allow us to further attract additional blue chip customers, partners, and collaborators."  





Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dyadic Issued New U.S. Patent
Dyadic International has been issued U.S. Patent No. 8,551,751 B2 entitled, "BX11 Enzymes Having Xylosidase Activity" by the United States Patent and Trademark Office.
Monday, November 11, 2013
Dyadic Welcomes New Chief Operating Officer
Danai Brooks will join the Company as Executive Vice President and Chief Operating Officer.
Friday, May 10, 2013
Scientific News
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!